Paradoxical Psoriasis: From its Many Faces to Possible Shared Therapeutic Targets
-
Published:2024-09
Issue:9
Volume:144
Page:2084-2085
-
ISSN:0022-202X
-
Container-title:Journal of Investigative Dermatology
-
language:en
-
Short-container-title:Journal of Investigative Dermatology
Author:
Maronese Carlo AlbertoORCID,
Costanzo AntonioORCID,
Gilliet MichelORCID,
Marzano Angelo ValerioORCID
Reference9 articles.
1. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study;Bissonnette;J Eur Acad Dermatol Venereol,2023
2. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis;Carrier;J Invest Dermatol,2011
3. IL-36 promotes systemic IFN-I responses in severe forms of psoriasis;Catapano;J Invest Dermatol,2020
4. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis;Conrad;Nat Commun,2018
5. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development;Fania;J Pathol Clin Res,2020